Swedish Orphan Biovitrum AB (publ)
SWB:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
SWB:B6E
|
SE |
|
Sawit Sumbermas Sarana Tbk PT
IDX:SSMS
|
ID |
|
A
|
Avista Corp
SWB:AV6
|
US |
|
C
|
Cronos Group Inc
NASDAQ:CRON
|
CA |
|
Telkom Indonesia (Persero) Tbk PT
IDX:TLKM
|
ID |
|
Ammo Inc
F:92P
|
US |
|
Amada Co Ltd
TSE:6113
|
JP |
|
Bonava AB (publ)
F:66B
|
SE |
|
InSilico Medicine Cayman TopCo
OTC:ISLMF
|
HK |
|
A
|
Arlo Technologies Inc
F:2VI
|
US |
|
T
|
Transgene SA
F:TGNA
|
FR |
|
W
|
Welsbach Technology Metals Acquisition Corp
OTC:WTMA
|
US |
|
P
|
Premier Foods PLC
SWB:FOJ1
|
UK |
|
Victory Mines Ltd
ASX:VIC
|
AU |
|
G
|
GlaxoSmithKline PLC
XBER:GS7
|
UK |
|
T
|
Tikehau Capital SCA
F:7TI
|
FR |
Bankruptcy Probability
Swedish Orphan Biovitrum AB (publ)'s probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Swedish Orphan Biovitrum AB (publ) Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SE |
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
150.4B SEK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.9B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
38.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Swedish Orphan Biovitrum AB (publ)'s probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Swedish Orphan Biovitrum AB (publ) has total debt of 7.9B SEK. This includes both short-term (0 SEK) and long-term (7.9B SEK) debt.
You can find a full breakdown on its Balance Sheet.
